Sermorelin: The First 29 Amino Acids of GHRH That Became a Research Tool

The Truncated Fragment That Worked

Native human GHRH is a 44-amino-acid peptide secreted by the hypothalamic arcuate nucleus. It travels through the hypothalamic-pituitary portal system to the anterior pituitary, where it binds the GHRH receptor on somatotroph cells and triggers growth hormone secretion. The full 44-residue molecule was characterized in the early 1980s, primarily through the work of Roger Guillemin's lab and others.

One of the early findings, useful for both research and pharmaceutical development, was that the receptor-binding activity is contained in the N-terminal 29 amino acids. Truncating the molecule to GHRH(1-29) preserves full receptor agonism. The remaining 15 residues serve mostly structural and possibly trafficking roles that are not required for the secretagogue activity.

This is the molecule that became Sermorelin. It is identical in sequence to the first 29 amino acids of native GHRH, with no chemical modifications.

Why DPP-IV Matters

The same property that makes Sermorelin biologically authentic — sequence identity with native GHRH — also limits its in vivo stability. Dipeptidyl peptidase-IV (DPP-IV), an enzyme widely distributed in plasma and tissue, cleaves peptides at the second N-terminal residue when that position contains an alanine or proline. Native GHRH has alanine at position 2 and is cleaved rapidly. Sermorelin, having identical sequence, is cleaved with the same kinetics.

The result is a plasma half-life of approximately 11-12 minutes in the published pharmacokinetic studies. That is short enough that single subcutaneous administration produces a brief, well-defined GHRH receptor stimulation followed by clearance. This is exactly the property you want in a diagnostic agent — you can dose, draw blood at defined timepoints, measure the GH response, and characterize somatotroph function. It is not the property you want in a chronic therapeutic, where shorter half-life means more frequent dosing or larger doses.

This pharmacokinetic limitation is what motivated the development of longer-acting GHRH analogs. CJC-1295 with DAC technology binds covalently to plasma albumin and extends half-life into the days. CJC-1295 without DAC (also known as Mod-GRF 1-29) replaces the DPP-IV-vulnerable alanine and several other residues to extend half-life to hours. These are downstream evolutions of the parent Sermorelin chemistry.

The Geref Era

Sermorelin was developed as Geref by Serono and approved by the FDA in 1997 for pediatric growth hormone deficiency. The use case was both diagnostic — to distinguish pituitary GH deficiency from hypothalamic GHRH deficiency — and therapeutic, for cases where stimulating endogenous GH was preferred to direct somatropin administration. Pediatric endocrinology was the primary clinical context.

The product was discontinued in the early 2000s. The reasons were commercial rather than scientific: recombinant somatropin became cheaper and more reliable for direct GH replacement, and arginine and clonidine stimulation tests largely replaced GHRH-based diagnostics for routine workup. Sermorelin remained available through compounding pharmacies in the United States and as a research compound globally, but it was no longer a packaged FDA-approved product.

The Research Tool

What Sermorelin retains, regardless of its commercial history, is its value as a research reagent. It is the most direct available probe for GHRH receptor pharmacology in animal models. Published applications include somatotroph response characterization in pituitary cell culture, in vivo GH pulsatility studies, and pharmacological dissection of GHRH-versus-ghrelin signaling pathways in the somatotrophic axis.

It is also useful as a pharmacokinetic reference compound. Any new GHRH analog with extended half-life is typically characterized against Sermorelin to quantify the half-life extension achieved.

What the Trials Established

The pediatric trials supporting the original Geref approval established that Sermorelin produces dose-dependent GH release in children with intact pituitary GHRH receptors but absent hypothalamic GHRH function. The diagnostic specificity is high. Therapeutic efficacy in pediatric GH deficiency was demonstrated in several smaller trials, with measurable height velocity improvements in responsive subgroups, but the magnitude was generally smaller than direct somatropin treatment.

Adult studies were limited. Some Phase II work in adults with adult-onset GH deficiency showed measurable GH and IGF-1 response, but the data is much smaller in scope than the pediatric record. Claims about Sermorelin in adult populations should be calibrated to that limited evidence base.

What Researchers Should Know

For laboratory work, Sermorelin's value is its sequence authenticity and short, well-characterized pharmacokinetics. It is not the right compound for studies that require extended GHRH receptor occupancy — the longer-acting analogs are better suited there. It is the right compound when you want to model native GHRH pulsatility, study acute somatotroph response, or use a pharmacological probe with a clean clinical reference dataset.

The historical FDA approval and the published pediatric trial record give Sermorelin something most peptides on the research market do not have: a documented human safety profile at clinically validated doses. That is a useful anchor for translational work, even when the specific application is not pediatric GH deficiency.

Sources: Guillemin et al., Science, 1982 (GHRH characterization); Walker et al., Journal of Clinical Endocrinology & Metabolism, 1990s (Sermorelin pharmacokinetics); FDA New Drug Application 20-443 (Geref, Serono, 1997); Thorner et al., Endocrine Reviews, 1989 (GHRH biology and clinical applications).